ArticleOncotarget2019

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced

Carla M L van Herpen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.